Slide 1: Full Year 2022 Results
Full Year 2022 Results Matthias Gaertner, CEO Falk Neukirch, CFO March 30, 2023
Slide 2: Executive summary, Financial overview, Guidance 2023, Appendix
1 Executive summary 2 Financial overview 3 Guidance 2023, growth story 4 Appendix 2
Slide 3: Highlights FY 2022
Executive summary Highlights FY 2022 • Overall successful year despite ongoing global crisis and uncertainties • Significant strengthening of the PST segment through acquisitions of NewCo Pharma GmbH Operations (January 2022) • Setting the course for 2023: Agreement on sterile manufacturing collabor
Slide 4: Q-on-Q growth impacted in Q4 by regulatory changes
Executive Summary Q-on-Q growth impacted in Q4 by regulatory changes Revenue in €m EBITDA pre¹ €m 419 369 399 399 15.3 393 354 14.1 14.3 319 316 11.1 10.2 9.5 10.0 8.8 174 163 160 130 4.8 4.3 2.7 3.8 margin 2.6 2.2 3.6 3.6 3.7 2.8 3.0 2.8 2.8 2.8 2.8 2.4 1.7 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2
Slide 5: Continuous and sustainable growth with significantly improved margin
Executive Summary Continuous and sustainable growth with significantly improved margin Revenue in €m EBITDA pre¹ in €m +18.7% + 42.8% 1,610 1,357 54.9 38.4 FY 2021 FY 2022 FY 2021 FY 2022 ¹ EBITDA pre is adjusted for special charges for stock options and expenses for M&A activities as well as from 2
Slide 6: Split by operative segments FY 2022 vs FY 2021: Significant rise of PST
Executive Summary Split by operative segments FY 2022 vs- FY 2021: Significant rise of PST Revenue by segment EBITDA pre1 by segment 14% 43% 5% 21% 2021 Patient-specific Therapies (PST) 2021 95% 88% 86% 69% Pharmaceutical Supply (PS) ¹ EBITDA pre is adjusted for special charges for stock options and
Slide 7: Excellent geographic coverage through strong nationwide network
Executive Summary Excellent geographic coverage through strong nationwide network of partners and own compounding facilities • 7 GMP1 / 2 blistering labs Hamburg • 2 central / 2 regional warehouses • Innovative IT-based platform Osnabruck Berlin (HQ) mediosconnect in 5 federal states Cologne • Aroun
Slide 8: Implementing our ESG strategy 2025
Executive Summary Implementing our ESG strategy 2025 Structural set-up, organization, responsibilities Steady improvement, sharpen our goals through measure control ESG strategy published Accomplishments and goals • 34 aims realized through 65 measures • E: Energy efficiency improvements through mov
Slide 9: Agenda: Financial overview
1 Executive summary 2 Financial overview 3 Guidance 2023, growth story 4 Appendix 9
Slide 10: FY 2022 – Financials
Financial Overview FY 2022 – Financials In € million FY 2022 FY 2021 ∆% Comments Revenue 1,610.8 1,357.4 18.7% • Revenue growth driven by NewCo Pharma Gross profit1 108.9 70.1 integration: inorganic (+15.3%) & organic 55.4% (+3.4%) gross margin in % 6.8% 5.2% EBITDA pre2 • Disproportionate increase
Slide 11: FY 2022 – Ongoing organic and inorganic revenue growth
Financial Overview FY 2022 – Ongoing organic and inorganic revenue growth FY YoY revenue in €m FY 2021 Organic Inorganic FY 2022 Comments Pharmaceutical Supply (PS) 1,294.5 40.2 55.6 1,390.3 • Inorganic Growth (+15.3%; 3.1% 4.2% 7.4% €+207.4m) driven by NewCo acquisition Patient-specific Therapies (
Slide 12: FY 2022 – EBITDA pre driven by acquisition of NewCo Pharma
Financial Overview FY 2022 – EBITDA pre1 driven by acquisition of NewCo Pharma FY YoY EBITDA pre1 in €m FY 2021 Organic Inorganic FY 2022 Comments Pharmaceutical Supply (PS) 33.7 0.4 3.9 38.0 • EBITDA pre of PS and PST segments 1.2% 11.6% 12.8% grew mainly inorganically Patient-specific Therapies (P
Slide 13: FY 2022 – Strong Group margin, mainly from increased PST share
Financial overview FY 2022 – Strong Group margin, mainly as a result of increased PST share Pharmaceutical Patient-specific Internal Services and Group Supply ‘PS‘ Therapies ‘PST’ IFRS consolidation In € million FY 2022 FY 2021 FY 2022 FY 2021 FY 2022 FY 2021 FY 2022 FY 2021 Total segment revenue 1,
Slide 14: Strong financing power – to invest in future growth
Financial overview Strong financing power – to invest in future growth Financing power in €m Available and future funds • Approx. €+37m annual operating cash flow • Approx. €-5m annual operating capex need (recently accomplished +10% capital manufacturing capacity just validated) increase1 Equity Ca
Slide 15: Agenda: Guidance 2023, growth story
1 Executive summary 2 Financial overview 3 Guidance 2023, growth story 4 Appendix 15
Slide 16: Guidance FY 2023 (1/2) – Ongoing growth story
Guidance 2023, growth story Guidance FY 2023 (1/2) – Ongoing growth story Revenue in €m EBITDA pre2 in €m Comments • Revenue1 expected to reach range of €1.6-1.8bn Up to +11.8% Up to +14.8% in 2023 (growth up to11.8% compared to 2022) • EBITDA pre1 expected to reach range of €56-63m in 2023 (growth
Slide 17: Guidance FY 2023 (2/2) – Main assumptions
Guidance 2023, growth story Guidance FY 2023 (2/2) – Main assumptions Main Assumptions for 2023 as of March 2023 Synergy effects as a result Especially in purchasing and Regulatory price reduction effective since Sep 1, 2022, of the integration of logistics for certain cytostatic drugs – negative im
Slide 18: Our strategic priorities moving forward
Guidance 2023, growth story Our strategic priorities moving forward Continue evolving out compounding infrastructure Core business: in Germany Germany Core business: Expand compounding within Internationalization Europe to gain continued growth, while increasing profitability New business: Diversifi
Slide 19: Prioritised markets are growing markets with attractive gross margins
Guidance 2023, growth story Prioritised markets are growing markets with attractive gross margins The total compounding market size in the The segment growth prioritised markets is rate in the prioritised estimated to be c.€2bn markets ranges from 5% – 65% The gross margins in The prioritised market
Slide 20: Advanced therapies manufacturing represents a highly attractive market opportunity
Guidance 2023, growth story Advanced therapies manufacturing represents a highly attractive market opportunity, aligned with Medios’ strengths Focus on Focus on patient- Why advanced Focus on patient-specific specific therapies? specialty therapies therapies pharma 2022 2025 Medios is already Advanc
Slide 21: Group Mid-term targets 2025–2027
Guidance 2023, growth story Group Mid-term targets 2025–2027 Mid- & long-term success depending on: Revenue • Successful implementation of adapted strategy > €2bn • Expansion of higher-margin PST business Increased • Patient-specific and advanced therapies, margins also via, EBITDA pre* margin • Int
Slide 22: Agenda: Appendix
1 Executive summary 2 Financial overview 3 Guidance 2023, growth story 4 Appendix 22
Slide 23: Key figures (1/2)
Key figures (1/2) in € thousand FY 2022 FY 2021 ∆ in % Q4 2022 Q4 2021 ∆ in % Revenue 1,610,777 1,357,408 18.7 399,380 368,643 8.3 Pharmaceutical Supply 1,390,296 1,294,531 7.4 345,914 352,786 -1.9 Patient-Specific Therapies 219,962 62,230 253.5 53,337 15,685 240.0 Services 518 648 -20.1 130 171 -24
Slide 24: Key figures (2/2)
Key figures (2/2) in € thousand FY 2022 FY 2021 ∆ in % Q4 2022 Q4 2021 ∆ in % Earnings per share (in €) Undiluted 0.77 0.37 108.1 0.10 -0.13 -23.1 Diluted 0.77 0.37 108.1 0.10 -0.11 -9.1 Investments (CAPEX) 5,064 12,821 -60.5 1,488 3,873 -61.1 Cash flow from operating activities 37,123 61,530 -39.7
Slide 25: Q4 2022 – Ongoing organic and inorganic revenue growth
Financial Overview Q4 2022 – Ongoing organic and inorganic revenue growth Q4 YoY revenue in €m Q4 2021 Organic Inorganic Q4 2022 Comments 352.8 -21.7 14.9 345.9 • Inorganic Growth (+14%; Pharmaceutical Supply €+51.4m) driven by NewCo 15.7 1.1 36.5 53.3 acquisition Patient-specific Therapies 0.2 0.0
Slide 26: Q4 2022 – EBITDA pre driven by acquisition of NewCo Pharma
Financial Overview Q4 2022 – EBITDA pre1 driven by acquisition of NewCo Pharma Q4 YoY EBITDA pre1 in €m Q4 2021 Organic Inorganic Q4 2022 Comments 9.9 -0.9 0.8 9.8 • EBITDA pre of PS and PST segments Pharmaceutical Supply grew exclusively inorganically Patient-specific Therapies 1.9 -0.1 2.5 4.3 • A
Slide 27: Q4 2022 – Impacted by regulatory changes
Financial overview Q4 2022 – Impacted by regulatory changes Pharmaceutical Patient-specific Internal Services and Group Supply ‘PS‘ Therapies ‘PST’ IFRS consolidation In € million Q4 2022 Q4 2021 Q4 2022 Q4 2021 Q4 2022 Q4 2021 Q4 2022 Q4 2021 Total segment revenue 364.7 360.8 65.2 20.3 -30.5 -12.4
Slide 28: Contact
Contact Claudia Nickolaus Head of Investor & Public Relations, ESG Communications Phone +49 30 232 566 800 c.nickolaus@medios.ag 28
Slide 29: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of contained herein are as up to date as is reasonably possible and are subject to revision in the the C
Slide 30: Full Year 2022 Results
Full Year 2022 Results Matthias Gaertner, CEO Falk Neukirch, CFO March 30, 2023